Home › Agent Hub › Agent Tools › Part D coverage by drug › Xeljanz
Agent Tools
Xeljanz is a brand of tofacitinib. What agents check before quoting it: how many 2026 Part D plans cover it, on which tier, with what restrictions and copays, by plan type, carrier and state.
In 2026, 1,612 of 5,496 Medicare Part D and Medicare Advantage drug plans (29.3%) list Xeljanz on their formulary, across 107 of 328 formularies. The most common placement is tier 5 (1,503 plans, 93.2% of those covering it). 1,612 of the covering plans require prior authorization (100%), 0 step therapy and 1,587 a quantity limit.
23 covering plans charge a flat copay for a 30-day supply at a preferred retail pharmacy after the deductible — median $0, 23 of them $0; 1,589 charge coinsurance instead — median 25% of the drug's cost. Once a member's out-of-pocket drug spending reaches $2,100 in 2026, covered drugs cost $0 for the rest of the year.
2025: 3,662 of 5,631 plans covered it (65%); 2026: 1,612 of 5,496 (29.3%).
Of 4,368 plans offered in both years, 6 added it to the formulary and 1,526 dropped it.
Among plans covering it both years, 16 moved it to a higher tier and 6 to a lower one; 0 added prior authorization and 0 removed it.
Medicare Part D paid for 103,278 30-day fills of Xeljanz in 2024 for about 12,575 enrollees, at an average total cost of $5,689.57 per 30-day fill (CMS Part D Prescribers by Geography and Drug, national).
Price Xeljanz and the rest of a client's list on every plan in their county.
Estimate Xeljanz costs by plan
Free tools for licensed insurance agents. Data from CMS public files; verify with plan documents before advising a client.
Counts are over every Medicare Advantage drug plan and stand-alone Part D plan in the CMS monthly formulary files, excluding employer plans. A plan counts as covering a drug when any strength or form of it is on the plan’s formulary; the tier, prior authorization, step therapy and quantity limit shown are the most favorable version on that formulary. Copays are for a 30-day supply at a preferred retail pharmacy after the deductible. This is a reference for licensed agents, not a plan recommendation; verify with the plan’s formulary before advising a client. Source: CMS Part D formulary files (release 09/16/2026). CMS formulary data.